Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cerebrolysin vs Donepezil in Mild to Moderate Alzheimer's Disease
NCT01822951Phase 4Withdrawn
- Sponsor
- EVER Pharma
- Primary completion
- Sep 2016
- Modality
- Native Peptides
- Countries
- 1
01
Overview
A Phase 4 trial of cerebrolysin in Alzheimer's disease (AD), sponsored by EVER Pharma. Status: withdrawn.
02
Drugs
cerebrolysin
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT01822951.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01822951.